2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.18 DaSilva

PP01.18 DaSilva - Abstract

Pdf Summary

A phase 2 study evaluated the safety and efficacy of PT-112 in patients with thymic epithelial tumors (TETs) who had previously undergone platinum-based chemotherapy. PT-112, a novel compound, showed promising clinical activity and tolerability without additional immune-related side effects. Among participants, stable disease was observed in 82% while 18% experienced disease progression. Notably, one patient exhibited a delayed response even after discontinuing PT-112 due to adverse events. The median progression-free survival was 15.0 months for thymoma patients and 6.1 months for thymic carcinoma patients. Common treatment-related adverse events included anemia, thrombocytopenia, fatigue, and peripheral neuropathy. Some patients showed increased levels of CD8 and activated CD4 T cells post-treatment, along with elevated pro-inflammatory cytokines and decreased levels of immunosuppressive serum analytes. Tumor biopsies revealed immune cell infiltration and increased expression of immune activation markers. These early findings suggest that PT-112 has potential in treating TETs by inducing immune activation without triggering new immune-related adverse events. The results support further investigation of PT-112 for thymic epithelial tumors.

Keywords

PT-112

thymic epithelial tumors

platinum-based chemotherapy

clinical activity

immune activation

progression-free survival

adverse events

immune-related side effects

tumor biopsies

immunosuppressive serum analytes